June 1977

Platelet-Inhibiting Drugs in Thrombotic Thrombocytopenic Purpura

Author Affiliations

From the Department of Medicine, University of Wisconsin, and Methodist Hospitals, Madison, Wis. Dr Eckel is now with the Department of Medicine, University of Washington, Seattle; Dr Crowell is now with Christian Medical College, Ludhiana, Punjab, India; Dr Bozdech is now with the Department of Medicine, University of California at San Francisco.

Arch Intern Med. 1977;137(6):735-737. doi:10.1001/archinte.1977.03630180019009

Two patients with thrombotic thrombocytopenic purpura were seen. Aspirin, dipyridamole, and sulfinpyrazone were administered to patient 1 after splenectomy, and administration of high-dose prednisone and methylprednisolone failed to induce remission. The platelet count rose, but the patient had a relapse when the dipyridamole dose was tapered. This condition responded to an increase of the drug, and the patient obtained a long-lasting remission. A splenectomy was not performed on patient 2, and all three platelet-inhibiting drugs, together with prednisone, were given. This resulted in a prompt remission that has been sustained for 29 weeks. Morphologic changes in the peripheral blood smear remained for several weeks after other features of the disease had resolved. Thus, in both cases, platelet-inhibiting drugs appeared to induce a remission.

(Arch Intern Med 113:735-737, 1977)